ARTICLES BY LOUIS

• Are You Cut Out To Be An Outsourcing Phenom?

  4/25/2022

  Outsourcing is a risk-laden operational strategy, but to a lesser degree if you’re an organization with an outsourcing professional like Kent Pryor. CEO or otherwise: Do you or your colleagues fit that bill? The answer could be vital to your chances of success.

• Call It What You Like, This Biotech Model Makes Money

  4/18/2022

  “We are a biotech that makes money,” replies Helen Torley, CEO, Halozyme, when I ask her what her company is exactly. A significant amount of money, along with notably high margins, and plenty of new drug opportunities. Here's the model for success.

• Halozyme's Outsourcing Tip: The External Manufacturing Site Lead

  4/11/2022

  Halozyme's API production has occurred at two U.S.-based CDMOs since its first commercial approval in 2013. The biotech works closely with both on new API generations and biologic processes, leading to additional regulatory filings. Here's a key ingredient to that success.

• The Hardest Job In All BioPharma: The CTO

  4/4/2022

  In this final look at Chief Technology Officers, all readers will find leadership lessons. CTOs are asking: What do we need to grow into our expanded roles? Top of the agenda: "Connecting as human beings, as innovative and committed leaders, serving all our stakeholders.” 

• The Incredible Story Of An Outsourcing Phenom

  4/1/2022

  In 1996, “while in grad school at MIT, my professor tossed me into the back of a truck along with the chemicals, and moved to The Scripps Research Institute in San Diego.” So recalls Kent Pryor on how he would wind up a component of the Southern California biotechnology boom, and an outsourcing phenom.

• Controlling Time: The Secret To Manufacturing

  3/29/2022

  An experienced CEO is undertaking a manufacturing risk and opportunity strategy. He's included CDMOs and other external experts in the analysis. That analysis now sits before the board. Key is how much capacity to build, how much to outsource. The main object is to control time.

• Awards, Revelations, Outsourcing For Success

  3/25/2022

  Nobody benefits if we can't continue to partner optimally for drug development and manufacturing activities. Here's our tangible assistance in ensuring just the opposite — that you have tools to select the right CDMOs to bring you prosperity, and new drugs and therapies to your patients. 

• Hire Your CTO Now, Then Get Help At Your CDMO

  3/21/2022

  Part 2 of our dive into the growing role of the Chief Technology Officer. We cover how and when to hire for the position, and how CDMOs can assist your CTO once on board.

• Optimized Collaborations From R&D To Manufacturing

  3/14/2022

  Paul Peter Tak, has been a professor, founded/chaired organizations and biopharma companies, and spent years at GSK before becoming CEO, Candel Therapeutics. He’s formed scientific liaisons and outsourcing partnerships at every phase of drug discovery, development, and manufacturing. Here’s one of those elements for each of these steps. 

• If You're Outsourcing, Your CTO Probably Needs A Hug

  3/7/2022

  You might want to check in on your Chief Technology Officer. “They’re at the center of the storm,” says a biopharma-industry consultant focused on the modern-day CTO. The role has become critical to a company’s success, impacts across the enterprise, and has become highly pressurized.